$NTLA

Intellia Therapeutics, Inc.

CIK:0001652130|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Collaboration revenue	$ 7,659	$ 14,245	$ 22,707	$ 30,872
Type of Revenue [Extensible List]			us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Operating expenses:
Research and development	82,595	97,035	$ 163,332	$ 205,462
General and administrative	37,824	27,206	72,667	56,213
Total operating expenses	120,419	124,241	235,999	261,675
Operating loss	(112,760)	(109,996)	(213,292)	(230,803)
Other income, net:
Interest income	5,797	7,402	11,002	16,005
Change in fair value of investments, net	329	1,339	(575)	(786)
Total other income, net	6,126	8,741	10,427	15,219
Net loss	$ (106,634)	$ (101,255)	$ (202,865)	$ (215,584)
Net loss per share, basic	$ (0.8)	$ (0.98)	$ (1.61)	$ (2.08)
Net loss per share, diluted	$ (0.8)	$ (0.98)	$ (1.61)	$ (2.08)
Weighted average shares outstanding, basic	133,480	103,732	126,057	103,617
Weighted average shares outstanding, diluted	133,480	103,732	126,057	103,617
Other comprehensive loss:
Unrealized (loss) gain on marketable securities	$ (790)	$ (404)	$ (2,062)	$ 48
Comprehensive loss	$ (107,424)	$ (101,659)	$ (204,927)	$ (215,536)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss			$ (202,865)	$ (215,584)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	$ 2,100	$ 2,500	4,284	4,972
Loss on disposal of property and equipment			153	0
Stock-based compensation			31,554	43,876
Accretion of investment discounts			(1,149)	(3,947)
Change in fair value of investments, net	(329)	(1,339)	575	786	$ 0
Changes in operating assets and liabilities:
Accounts receivable			2,147	(2,836)
Prepaid expenses and other current assets			(14,391)	5,373
Operating lease right-of-use assets			17,918	16,151
Other assets			538	(24,415)
Accounts payable			(8,506)	(4,431)
Accrued expenses			(5,591)	(13,583)
Deferred revenue			(7,290)	(9,224)
Operating lease liabilities			(17,836)	(45,690)
Net cash used in operating activities			(200,459)	(248,552)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment			(1,888)	(974)
Proceeds from sale of property and equipment			90	0
Purchases of marketable securities			(267,358)	(138,809)
Sales and maturities of marketable securities			193,894	341,021
Net cash (used in) provided by investing activities			(75,262)	201,238
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from options exercised			16	0
Issuance of shares through employee stock purchase plan			1,520	1,237
Net cash provided by financing activities			229,685	14,652
Net decrease in cash, cash equivalents and restricted cash equivalents			(46,036)	(32,662)
Cash, cash equivalents and restricted cash equivalents, beginning of period			167,568	202,787	202,787
Cash, cash equivalents and restricted cash equivalents, end of period	121,532	170,125	121,532	170,125	167,568
Reconciliation of cash, cash equivalents and restricted cash equivalents to condensed consolidated balance sheet:
Cash and cash equivalents	106,128	156,172	106,128	156,172	155,464
Restricted cash equivalents, included in investments and other assets	15,404	13,953	15,404	13,953
Total cash, cash equivalents and restricted cash equivalents	$ 121,532	$ 170,125	121,532	170,125	$ 167,568
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Purchases of property and equipment unpaid at period end			57	0
Reduction of right-of-use assets from remeasurement of lease liabilities			2,083	61,917
Proceeds from at-the-market offerings unpaid at period end			0	307
At The Market Offerings
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock			33,569	13,415
Follow-on Public Offering
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock			$ 194,580	$ 0

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 106,128	$ 155,464
Marketable securities	331,631	294,420
Accounts receivable	7,321	9,468
Prepaid expenses and other current assets	82,752	68,359
Total current assets	527,832	527,711
Marketable securities - noncurrent	190,595	155,250
Property and equipment, net	15,058	17,671
Operating lease right-of-use assets	85,954	105,955
Investments and other assets	37,725	35,540
Total assets	857,164	842,127
Current liabilities:
Accounts payable	11,714	20,252
Accrued expenses	44,334	49,862
Current portion of operating lease liability	23,344	26,480
Current portion of deferred revenue	0	7,290
Total current liabilities	79,392	103,884
Long-term operating lease liability	50,066	66,849
Total liabilities	129,458	170,733
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock, $0.0001 par value; 240,000,000 shares authorized at June 30, 2026 and December 31, 2025; 140,018,200 and 116,317,060 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	14	12
Additional paid-in capital	3,521,681	3,260,444
Accumulated other comprehensive income	(1,030)	1,032
Accumulated deficit	(2,792,959)	(2,590,094)
Total stockholders’ equity	727,706	671,394
Total liabilities and stockholders' equity	$ 857,164	$ 842,127